Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Goldenwell Biotech (GWLL) EBITDA Margin (2020 - 2024)

Goldenwell Biotech (GWLL) has disclosed EBITDA Margin for 5 consecutive years, with 45674.05% as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, EBITDA Margin fell 3767444.0% year-over-year to 45674.05%, compared with a TTM value of 19546.2% through Sep 2025, up 248970.0%, and an annual FY2024 reading of 19853.96%, down 1354535.0% over the prior year.
  • EBITDA Margin was 45674.05% for Q4 2024 at Goldenwell Biotech, down from 16808.08% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 22392.55% in Q4 2022 and bottomed at 45674.05% in Q4 2024.
  • Average EBITDA Margin over 5 years is 5984.58%, with a median of 3319.98% recorded in 2021.
  • The sharpest move saw EBITDA Margin skyrocketed 2611252bps in 2022, then tumbled -3767444bps in 2024.
  • Year by year, EBITDA Margin stood at 2920.0% in 2020, then dropped by -27bps to 3719.96% in 2021, then surged by 702bps to 22392.55% in 2022, then tumbled by -136bps to 7999.62% in 2023, then crashed by -471bps to 45674.05% in 2024.
  • Business Quant data shows EBITDA Margin for GWLL at 45674.05% in Q4 2024, 16808.08% in Q2 2024, and 7999.62% in Q4 2023.